MedTrace Logo

Tranexamic Acid Contribution in the Prevention of Perioperative Bleeding in Thoracic Surgery

NCT04224116 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-01-13

No results posted yet for this study

Summary

Bleeding after thoracic surgery is a major cause of perioperative hemodynamic instability and transfusion requirement, which can lead to a rise of morbidity, mortality and costs.

The objective of this study is to evaluate the efficiency of tranexamic acid (TA) in the prevention of perioperative bleeding in thoracic hemorrhagic surgery.

Conditions

Interventions

DRUG

Tranexamic acid injection

to receive tranexamic acid (25mg/kg) in bolus at induction followed by 2mg/kg/h in continuous infusion until the end of the act.

DRUG

SSI

Serum Salin isotonic injected

Sponsors & Collaborators

  • University Tunis El Manar

    lead OTHER

Principal Investigators

  • Tahar Mestiri, Professor · university Manar Tunis

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-01-01
Primary Completion
2019-10-02
Completion
2019-10-02

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04224116 on ClinicalTrials.gov